Holly Branthoover to Immunotherapy, Adoptive
This is a "connection" page, showing publications Holly Branthoover has written about Immunotherapy, Adoptive.
Connection Strength
0.068
-
Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients. J Immunother Cancer. 2023 10; 11(10).
Score: 0.035
-
Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Clin Cancer Res. 2022 12 15; 28(24):5317-5329.
Score: 0.033